Prasad Suyash

CMO and Head of R&D at TSHA; Senior VP & Chief Med Officer at Audentes Therapeutics, Inc.

Sold, on record
$4.1M
Dollars the filings state
Form 4 sales
11
Latest Jul 6, 2022
Form 144 notices
0
Proposed sales
Companies
2
Filed as an executive or holder

Companies

Sales by reason

0
Routine
0
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, last 12 months.

Sales chart range

Sales by company

Shares sold, every Form 4 sale on record.

Timeline

  1. 1 Form 4 sale Audentes Therapeutics, Inc.Unusual
    Mar 26 2018

    Sold 2,200 shares at $30.00 ($66k)

    Prasad Suyash, Senior VP & Chief Med Officer

    Sold 100% of holdings ($66k position)0 shares leftFirst sale on recordFiling

  2. 2 Form 4 sale Audentes Therapeutics, Inc.Unusual
    Jul 2 +98 days

    Sold 10,000 shares at $38.41 ($384k)

    Prasad Suyash, Senior VP & Chief Med Officer

    Sold 100% of holdings ($384k position)0 shares left1.3x usual sizeFiling

  3. 3 Form 4 sale Audentes Therapeutics, Inc.Unusual
    Oct 1 +91 days

    Sold 10,000 shares at $36.88 ($369k)

    Prasad Suyash, Senior VP & Chief Med Officer

    Sold 100% of holdings ($369k position)0 shares left1.3x usual sizeFiling

  4. 4 Form 4 sale Audentes Therapeutics, Inc.Unusual
    Feb 25 +147 days

    Sold 10,000 shares at $30.06 ($301k)

    Prasad Suyash, Senior VP & Chief Med Officer

    Sold 35.4% of holdings ($849k position)18,236 shares left1.3x usual sizeFiling

  5. 5 Form 4 sale Audentes Therapeutics, Inc.Unusual
    May 13 +77 days

    Sold 10,000 shares at $36.98 ($370k)

    Prasad Suyash, Senior VP & Chief Med Officer

    Sold 35.4% of holdings ($1M position)18,236 shares left1x usual sizeFiling

  6. 6 Form 4 sale TSHAPlan not stated
    Jul 1 +780 days

    Sold 79,000 shares at $22.63 ($1.8M)

    Prasad Suyash, CMO and Head of R&D

    Sold 11.7% of holdings ($15.2M position)593,589 shares leftFirst sale on recordFiling

  7. 7 Form 4 sale TSHAPlan not stated
    Jul 1 +365 days

    Sold 50,139 shares at $3.65 ($183k)

    Prasad Suyash, CMO and Head of R&D

    Sold 8.4% of holdings ($2.2M position)543,450 shares leftFiling

  8. 8 Form 4 sale TSHAPlan not stated
    Jul 6 +5 days

    Sold 12,861 shares at $3.70 ($48k)

    Prasad Suyash, CMO and Head of R&D

    Sold 2.4% of holdings ($2M position)530,589 shares leftFiling

Every transaction

Loading transactions…

Sales and notices (11)

Form 144 notices and Form 4 sales by Prasad Suyash
Source
Jul 6, 2022TSHACMO and Head of R&DForm 4 sale12,861$48k2.4%Plan not statedSEC
Jul 1, 2022TSHACMO and Head of R&DForm 4 sale50,139$183k8.4%Plan not statedSEC
Jul 1, 2021TSHACMO and Head of R&DForm 4 sale79,000$1.8M11.7%Plan not statedSEC
May 13, 2019Audentes Therapeutics, Inc.Senior VP & Chief Med OfficerForm 4 sale10,000$370k35.4%UnusualSEC
Feb 25, 2019Audentes Therapeutics, Inc.Senior VP & Chief Med OfficerForm 4 sale10,000$301k35.4%UnusualSEC
Oct 1, 2018Audentes Therapeutics, Inc.Senior VP & Chief Med OfficerForm 4 sale10,000$369k100.0%UnusualSEC
Jul 2, 2018Audentes Therapeutics, Inc.Senior VP & Chief Med OfficerForm 4 sale10,000$384k100.0%UnusualSEC
Mar 26, 2018Audentes Therapeutics, Inc.Senior VP & Chief Med OfficerForm 4 sale2,200$66k100.0%UnusualSEC
Dec 1, 2017Audentes Therapeutics, Inc.Senior VP & Chief Med OfficerForm 4 sale8,000$228k100.0%UnusualSEC
Sep 1, 2017Audentes Therapeutics, Inc.Senior VP & Chief Med OfficerForm 4 sale8,000$172k100.0%UnusualSEC
Mar 29, 2017Audentes Therapeutics, Inc.Senior VP & Chief Med OfficerForm 4 sale7,800$234k100.0%UnusualSEC